Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute Effect of Empagliflozin vs Dapagliflozin on PWV in T2DM
NCT05109949Phase 3Unknown
- Sponsor
- Centro Universitario de Ciencias de la Salud
- Start
- Mar 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin 10 mg, Empagliflozin 25 mg and Placebo (3 arms). Primary endpoint: Pulse Wave Velocity at 7 days. Status: unknown.
02
Drugs
empagliflozindapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05109949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05109949.